Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
Status:
Terminated
Trial end date:
2016-07-29
Target enrollment:
Participant gender:
Summary
The objectives of this trial are to evaluate the safety, tolerability, maximum tolerated dose
(MTD), pharmacokinetics and preliminary efficacy of volasertib in two dosing schedules of
intravenous volasertib as monotherapy or in combination with azacitidine in patients with
myelodysplastic syndrome (MDS) after hypomethylating agents (HMA) treatment failure.